This HTML5 document contains 65 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB08815/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB08815/identifier/chebi/
n11http://www.rxlist.com/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB08815/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB08815/identifier/kegg-drug/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB08815/identifier/drugbank/
n19http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08815
rdf:type
n3:Drug
n3:description
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)
n3:dosage
n5:271B5681-363D-11E5-9242-09173F13E4C5 n5:271B567A-363D-11E5-9242-09173F13E4C5 n5:271B567B-363D-11E5-9242-09173F13E4C5 n5:271B567C-363D-11E5-9242-09173F13E4C5 n5:271B567D-363D-11E5-9242-09173F13E4C5 n5:271B5678-363D-11E5-9242-09173F13E4C5 n5:271B5679-363D-11E5-9242-09173F13E4C5 n5:271B567E-363D-11E5-9242-09173F13E4C5 n5:271B567F-363D-11E5-9242-09173F13E4C5 n5:271B5680-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Apr 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23545936 # Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22849428
n3:group
approved
n3:halfLife
40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours
n3:indication
Treatment of schizophrenia.
owl:sameAs
n7:DB08815
dcterms:title
Lurasidone
adms:identifier
n13:63402-312-30 n14:Lurasidone n15:DB08815 n16:D04820 n18:70735
n3:mechanismOfAction
Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.
n3:patent
n17:5532372
n3:routeOfElimination
Urine (~9%) and feces (~80%)
n3:synonym
Lurasidona Lurasidonum
n3:volumeOfDistribution
6173 L
n8:hasAHFSCode
n9:28-16-08-04%20
n3:foodInteraction
When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours.
n3:proteinBinding
~99% bound to serum proteins.
n3:salt
foaf:page
n11:latuda-drug.htm n21:lurasidone.html
n3:IUPAC-Name
n4:271B5686-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B568C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B568B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5688-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5689-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B568A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5684-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5685-363D-11E5-9242-09173F13E4C5 n4:271B5682-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5683-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n19:N05AE05
n3:H-Bond-Acceptor-Count
n4:271B5692-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5693-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B568D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B568E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5690-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B568F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5691-363D-11E5-9242-09173F13E4C5
n3:absorption
Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content. Bioavailability = 9-19%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
367514-87-2
n3:clearance
3902 mL/min
n3:Bioavailability
n4:271B5697-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5699-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B569A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5696-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5695-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5698-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5687-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5694-363D-11E5-9242-09173F13E4C5